AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05384743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Monotherapy
Description: Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
Study NCT04542291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin will be provided for this trial
Study NCT04542291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOSENSE meters
Description: -Being used in this trial to evaluate utility for assessing breath ketones
Study NCT05111834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised resistance training plus nutritional endorsement
Description: resistance training 2x per week, nutritional endorsement/therapy based on individual needs
Study NCT05111834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional endorsement
Description: nutritional endorsement/therapy based on individual needs
Study NCT04630340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STEADES-2
Description: In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
Study NCT06663046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single dose injection of certain dose of UWD-00B
Description: Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-00B cells
Study NCT05016128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine is used for preventing postoperative hyperalgesia,thus reducing the patient's acute postoperative pain
Study NCT05016128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline is used for control
Study NCT06598007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT3001
Description: CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.
Study NCT05823662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
Study NCT06312631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: installation and collection of accelerometers
Description: The accelerometer quantitatively reports the spontaneous use of the upper limb in daily life. It counts the number of voluntary movements of the upper limbs. The amount of movement of the paretic upper limb will be expressed as a percentage of the movements of the non-paretic limb.
Study NCT05855746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Pill
Description: Participant receive, in addition to standard of care therapy, six months of colchicine (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization. The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.~During the six months of the treatment administration, in case of severe adverse reaction (such as nausea and/or diarrhea during five days), a dose reduction could be considered by the investigator: half of the study protocol dose could be accepted (0.5 mg per day in the morning). In case of remaining adverse reactions, the study drug should be stopped.
Study NCT05855746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.
Study NCT05725564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAST (Functional Activity Strength Training)
Description: Daily exercise intervention including functional resistance exercises and personalized coaching.
Study NCT05725564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Band Together
Description: 3 times weekly group exercise over Zoom featuring strength and balance exercises for 45 minutes
Study NCT05725564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Change Technique
Description: Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence
Study NCT05725564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Change Technique
Description: Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence
Study NCT06465459 — intervention group
Intervention type: PROCEDURE
Intervention: LAMBRE device implantation
Description: LAMBRE device implantation
Study NCT06396806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indocyanine green fluorescence imaging lymphatic tracing
Description: At the end of routine operation, indocyanine green was used for lymph node tracing, and further lymph node dissection was performed according to the tracer results.
Study NCT05772104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shugan Jieyu Capsules
Description: Oral, 4 Capsules, BID
Study NCT05772104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shugan Jieyu Capsules Placebo
Description: Drug: Shugan Jieyu Capsules Placebo, Oral，4 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID
Study NCT06346067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naporafenib
Description: Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor
Study NCT06346067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine IV - Day 1
Study NCT06346067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle
Study NCT06346067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
Study NCT06346067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
Study NCT06253507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47
Description: Cryopreserved autologous CD34+ cells transduced ex vivo with the pCCLCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use.~The minimum cell dose for infusion is 3 x 10\^6 CD34+/kg.
Study NCT04996069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crest Whitening Emulsions
Description: Subjects with Xerostomia will be asked to apply the study intervention product to their teeth up to 4 times per day for 1 week to investigate if the study intervention product increases saliva production in this dry mouth populaiton.
Study NCT06137677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet Snack
Description: A sweet food will be served for the snack
Study NCT06137677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Savory Snack
Description: A savory food will be served for the snack
Study NCT06671067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote dielectric sensing system
Description: The remote dielectric sensing (ReDS) system is a non-invasive medical device that emits a low-power electromagnetic signal through the chest and lungs, which can accurately measure changes in lung fluid concentration.
Study NCT06673186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overdenture
Description: Patient satisfaction (primary outcome) was measured by a visual analog scale (VAS). OHRQoL (secondary outcome) was measured by oral health impact profile (OHIP-14). Questions of VAS and OHIP-14 were evaluated after 3 months The patients were divided into two equal groups.
Study NCT06673303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic perceptual discrimination task
Description: The study featured two task conditions, each of which required the integration of information from both stimulus dimensions. In each condition, participants viewed a stimulus containing motion and color information and were required to specify one of two possible responses. Within each condition, rules and the response mapping changed occasionally, but always by changing on a fixed feature dimension (ie. rightward/purple, leftward/orange). These uncued intra-dimensional shifts involved translational shifts in the learning boundary, requiring them to adapt their decision making within a familiar dimension. These shifts compelled participants to continuously adjust their learning strategies by focusing on the most relevant feature dimension.
Study NCT06673303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Participant brain imaging data will be collected concurrently while performing the perceptual discrimination task.
Study NCT06672653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The monoterpenoid zinc tetra-ascorbo-camphorate (C14)
Description: The trial phase will consist of hospital administration by vaginal syringe of 5ml of 1% C14, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13). Gynaecological follow-up with HPV molecular testing and cervical smear will be performed two days after each course of treatment at S2, S6, S10, S14 and 2 weeks after the last course of treatment (S16). Unprotected sexual intercourse will not be permitted during each course of treatment, and for at least 72 hours before each genital swab.
Study NCT06672653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water group
Description: Instead of C14, distilled water will be administered in this group.
Study NCT06672614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Exercise Hot Water Immersion
Description: Participants will cycle for 60 minutes at 50% of maximal oxygen uptake (VO2 max) followed by 30 minutes post-exercise hot water immersion (40oC) for 5 consecutive days.
Study NCT06672614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants will cycle for 60 minutes at 50% maximal oxygen uptake (VO2 max) for 5 consecutive days. There is no water immersion following the exercise.
Study NCT06671990 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vericiguat
Description: Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
Study NCT06671990 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
Study NCT06671652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Duyugoda igalenisodi (Starting again the right way)
Description: Participants in the intervention arm will receive training and resources to build community resources and programming
Study NCT06671158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Individual psychotherapy for weekly 12-sessions
Study NCT06671158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Individual psychotherapy for weekly 12-sessions
Study NCT06598397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) Counseling
Description: Six sessions of phone counseling over 10-12 weeks with MI counselor trained in motivational interviewing and tobacco use treatment.
Study NCT06598397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Eight sessions of informal counseling with an experienced peer former smoker living with HIV to model healthy behavior and provide practical advice and tips for quitting based on their lived experience.
Study NCT06598397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills-based Text Messaging
Description: NCI's 8-week text messaging smoking cessation program, smokefreeTXT.gov.
Study NCT06598397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination NRT
Description: If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.
Study NCT04867317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
Study NCT04867317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
Study NCT06671964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anthropometric measurements
Description: Anthropometric measurements of the students, including weight, height, muscle mass, fat quantity, and waist circumference, were measured. The WHO BMI charts were utilized for classification. Stratified Random selection
Study NCT06671964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: The collection of data was performed using the Atlas questionnaire (Al-Hazzaa et al., 2011) and nutrition knowledge and healthy lifestyle behavior questionnaire (Kalender et al., 2011) with additional questions related to self-efficacy and dietary practices adapted from the literature (Becher, 2009; Voss et al., 2017; Kowalski et al., 2004). Stratified Random selection
Study NCT05229822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LBP
Description: Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
Study NCT05229822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sCD14-ST
Description: Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
Study NCT05229822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 16s rRNA
Description: Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.
Study NCT05464719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Given by IV
Study NCT05810025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealRisks
Description: RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
Study NCT06671964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational sessions
Description: The topics that covered included a healthy eating lifestyle, energy balance, food portion control, healthy snacking, the importance of physical activity and healthy eating, dietary practices, and nutrition-related self-efficacy.
Study NCT06227325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48 combined with Sintilimab and XELOX
Description: RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1；Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks
Study NCT06672354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: 1- Otago Exercise Program: i) This exercise program will consist of strengthening, balance exercises and walking plan. The OEP will be performed according to the following: 5 min warm-up, 10 min resistance training and 15 min balance exercises.~ii) The strength training protocol targets, on hip abductors, knee flexors, knee extensors, plantarflexors, and dorsiflexors.All exercises will be performed for 10 repetitions. This protocol recommends strength training 3 days per week.~iii) The balance retraining protocol incorporates various exercises. The exercises progress in difficulty through four levels, with Level 1 being the easiest and Level 4 the most challenging. Balance exercises will progress from holding onto a stable supporting structure such as heavy furniture to perform the exercises independent of the support. The protocol recommends participants to carry out balance exercises 3 days a week.~iv) Participants will be instructed to walk at their usual pace for 30 minutes, twice
Study NCT06672354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Immersive Virtual Reality Training
Description: In this interventional group, VR training exercises will be performed by using Xbox Kinect, which includes a Kinect sensor.-The monitor or Tv screen will recognize the movements of participants via camera and infra-red motion sensors.-In order to perform simulated exercises in each session, the participant will be positioned at 1.5-2 meter from the monitor or TV screen.-The virtual reality training exercises will include Kinect Adventure games (Rally Ball, 20,000 leaks, Reflex Ridge) and Sports pack 1 games (Super Saver, Target Kick, Body ball).-Exercises will be continued for 30-45 minutes each session, for 3 alternate days per week for a total period of 12 weeks.
Study NCT05295615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECHS AD Device
Description: Pulsed electromagnetic therapy device
Study NCT06013800 — intervention group
Intervention type: OTHER
Intervention: Measurement of sodium levels
Description: Patients will get measurements of sodium levels daily in the first 48 hours, then daily or every other day until normal sodium levels (>135mEq/L).
Study NCT05075655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound guided miniforceps biopsy and transbronchial needle aspiration
Description: Mediastinal node is sampled using three path of classic ultrasound guided transbronchial needle aspiration (EBUS-TBNA).~A reduce size forceps is then inserted inside the mediastinal node via the duc EBUS-TBNA made and biopsies (EBUS-MFB) are made using real time ultrasound guidance.
Study NCT05633979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Given by IV (vein)
Study NCT05633979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat
Description: Given by PO